GIGI DIAMOND M.D.
Prescription History 1295757359
Internal Medicine - Infectious Disease in Livingston, NJ

NPI Status: Active since July 24, 2006

Contact Information

349 E NORTHFIELD RD
SUITE 200
LIVINGSTON, NJ
ZIP 07039
Phone: (973) 597-0900
Fax: (973) 597-0910

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for GIGI DIAMOND M.D., an active Infectious Disease specialist practicing in Livingston, NJ. Our medical registry currently tracks 11 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 472 documented patient claims. Among these therapy options, the most frequently utilized medication is Biktarvy, which accounts for 303 claims alone.


Biktarvy

Generic Formulation: Bictegrav/Emtricit/Tenofov AlaSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 303
30-Day Fills 317.0
Days Supply 9,510
NJ State Average Benchmarks
Peer Average Claims74.0
Peer Average 30-Day Fills76.3
Peer Average Days Supply2,279
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 309.5% higher than the standard regional baseline profile for NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,262,860.29 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,167.86

State Avg Cost Per Claim

$3,949.33

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination product is used by itself to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of 3 different drugs: bictegravir, emtricitabine, and tenofovir alafenamide. Bictegravir is called an integrase strand transfer inhibitor-INSTI. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor. Emtricitabine and tenofovir alafenamide are often called NRTIs. Bictegravir/emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Cefazolin Sodium

Generic Formulation: Cefazolin SodiumSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 79
NJ State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills21.0
Peer Average Days Supply135
Conservative Utilization

This provider writes prescriptions for this formulation 45.0% less frequently than the standard regional baseline metric for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $427.85 across this reporting matrix range.

Provider Avg Cost Per Claim

$38.90

State Avg Cost Per Claim

$51.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.

Therapeutic Applications

Cefazolin is an antibiotic used to treat a wide variety of bacterial infections. It may also be used before and during certain surgeries to help prevent infection. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria.

Descovy

Generic Formulation: Emtricitabine/Tenofov AlafenamSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 35
30-Day Fills 35.0
Days Supply 1,050
NJ State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills34.3
Peer Average Days Supply999
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $80,501.14 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,300.03

State Avg Cost Per Claim

$2,171.65

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of two different drugs: emtricitabine and tenofovir alafenamide. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor. They are often called NRTIs. This product should not be used by itself to help control HIV infection. Doing so can make your treatment less effective. Use combination treatment with at least one other HIV medication. This product is also approved in the US to help prevent HIV infection in people who have a high risk for infection. Some things that increase risk include having a partner infected with HIV, having unprotected sex, having multiple sex partners, infection with a sexually transmitted disease-STD, or use/abuse of drugs or alcohol. Emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Edurant

Generic Formulation: Rilpivirine HclSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
NJ State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills23.0
Peer Average Days Supply643
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $16,043.28 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,458.48

State Avg Cost Per Claim

$1,341.22

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A diarylpyrimidine derivative and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 that is used in the treatment of HIV INFECTIONS. It is also used in combination with other ANTI-HIV AGENTS, since ANTIVIRAL DRUG RESISTANCE emerges rapidly when it is used alone.

Therapeutic Applications

Rilpivirine is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This medication is usually prescribed to people who have not taken any HIV medications before. Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). It blocks the virus from growing and infecting more cells. Rilpivirine is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Ertapenem

Generic Formulation: Ertapenem SodiumSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 108
NJ State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills22.7
Peer Average Days Supply125
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,436.79 across this reporting matrix range.

Provider Avg Cost Per Claim

$555.11

State Avg Cost Per Claim

$529.70

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of Gram-positive and Gram-negative bacterial infections including intra-abdominal infections, acute gynecological infections, complicated urinary tract infections, skin infections, and respiratory tract infections. It is also used to prevent infection in colorectal surgery.

Therapeutic Applications

Ertapenem is used to prevent and treat a wide variety of bacterial infections. This medication is known as a carbapenem-type antibiotic. It works by stopping the growth of bacteria.

Genvoya

Generic Formulation: Elviteg/Cob/Emtri/Tenof AlafenSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 15
30-Day Fills 29.0
Days Supply 870
NJ State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills31.9
Peer Average Days Supply951
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $112,055.70 across this reporting matrix range.

Provider Avg Cost Per Claim

$7,470.38

State Avg Cost Per Claim

$4,010.29

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of the ANTI-HIV AGENTS elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate that is used in the treatment of HIV INFECTIONS.

Therapeutic Applications

This product is used to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product contains 4 different medications: elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide. Elvitegravir is known as an integrase inhibitor. Cobicistat helps elvitegravir work better. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor; both kinds of drugs are often called NRTIs. Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Juluca

Generic Formulation: Dolutegravir/RilpivirineSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 18
30-Day Fills 32.0
Days Supply 960
NJ State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills34.1
Peer Average Days Supply1,021
Conservative Utilization

This provider writes prescriptions for this formulation 45.5% less frequently than the standard regional baseline metric for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $98,987.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$5,499.32

State Avg Cost Per Claim

$3,401.70

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Dolutegravir/rilpivirine is used to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Dolutegravir is an integrase inhibitor while rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). Both drugs block the virus from growing and infecting more cells. Dolutegravir/rilpivirine is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Odefsey

Generic Formulation: Emtricitab/Rilpiviri/Tenof AlaSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
NJ State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills33.6
Peer Average Days Supply1,007
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 62.5% less volume than the regional standard for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $43,549.56 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,629.13

State Avg Cost Per Claim

$3,606.24

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains 3 different medications: emtricitabine, rilpivirine, and tenofovir alafenamide. It is used to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Emtricitabine and tenofovir alafenamide belong to a class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs). Rilpivirine belongs to a class of drugs known as non-nucleoside reverse transcriptase inhibitors (NNRTIs). Emtricitabine/rilpivirine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Prezcobix

Generic Formulation: Darunavir/CobicistatSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
NJ State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills33.0
Peer Average Days Supply961
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 61.3% less volume than the regional standard for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $31,244.54 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,603.71

State Avg Cost Per Claim

$2,451.23

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of two different drugs: darunavir and cobicistat. Darunavir belongs to a class of drugs known as protease inhibitors. Cobicistat is used to increase (boost) the levels of darunavir. Darunavir/cobicistat is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Sulfamethoxazole-Trimethoprim

Generic Formulation: Sulfamethoxazole/TrimethoprimSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 14.6
Days Supply 231
NJ State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills31.5
Peer Average Days Supply434
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 60.7% less volume than the regional standard for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9.53 across this reporting matrix range.

Provider Avg Cost Per Claim

$0.87

State Avg Cost Per Claim

$5.67

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.

Therapeutic Applications

This medication is a combination of two antibiotics: sulfamethoxazole and trimethoprim. It is used to treat a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections). It is also used to prevent and treat a certain type of pneumonia (pneumocystis-type). This medication should not be used by children less than 2 months of age due to the risk of serious side effects. This medication treats only certain types of infections. It will not work for viral infections (such as flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Tivicay

Generic Formulation: Dolutegravir SodiumSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 27
30-Day Fills 27.0
Days Supply 810
NJ State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills46.6
Peer Average Days Supply1,283
Conservative Utilization

This provider writes prescriptions for this formulation 40.0% less frequently than the standard regional baseline metric for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $61,884.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,292.03

State Avg Cost Per Claim

$2,191.99

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Dolutegravir is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Dolutegravir belongs to a class of drugs known as integrase inhibitors. It blocks the virus from growing and infecting more cells. Dolutegravir is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like GIGI DIAMOND M.D. provides transparency into local medical care patterns within Livingston, NJ.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Infectious Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.